Allergy Therapeutics.
69 announcements.
69 announcements.
Time | Date | Ticker | Company | Announcement |
---|---|---|---|---|
07:00 | 31-03-2025 | AGY | Allergy Therapeutics | Interim Results for six months ended 31 Dec 2024 |
07:00 | 27-03-2025 | AGY | Allergy Therapeutics | Advancement to final phase of PROTECT trial |
07:00 | 03-03-2025 | AGY | Allergy Therapeutics | New Executive Long Term Incentive Awards |
07:00 | 27-02-2025 | AGY | Allergy Therapeutics | Presentations at 2025 AAAAI / WAO Joint Congress |
07:00 | 17-02-2025 | AGY | Allergy Therapeutics | Grass MATA MPL Phase III data published in Allergy |
07:00 | 14-02-2025 | AGY | Allergy Therapeutics | Grant of Options |
07:00 | 28-01-2025 | AGY | Allergy Therapeutics | Half Year Trading update |
07:00 | 22-01-2025 | AGY | Allergy Therapeutics | PDMR Dealing and Total Voting Rights |
07:00 | 15-01-2025 | AGY | Allergy Therapeutics | Director/PDMR Shareholding |
13:41 | 19-12-2024 | AGY | Allergy Therapeutics | Exercise of Options and Total Voting Rights |
16:19 | 17-12-2024 | AGY | Allergy Therapeutics | Block Listing Interim Review |
15:33 | 16-12-2024 | AGY | Allergy Therapeutics | Result of Annual General Meeting |
07:00 | 04-12-2024 | AGY | Allergy Therapeutics | Positive Interim Data from PROTECT Trial |
07:00 | 27-11-2024 | AGY | Allergy Therapeutics | First Patient Dosed in G308 Paediatric Trial |
07:00 | 25-11-2024 | AGY | Allergy Therapeutics | Submission of MAA for Grass MATA MPL |
07:00 | 21-11-2024 | AGY | Allergy Therapeutics | Notice of 2024 Annual General Meeting |
07:00 | 06-11-2024 | AGY | Allergy Therapeutics | Audited Preliminary Results 2024 |
07:00 | 21-10-2024 | AGY | Allergy Therapeutics | Commencement of Phase III Paediatric Trial |
07:00 | 16-10-2024 | AGY | Allergy Therapeutics | Update on funding |
07:00 | 01-10-2024 | AGY | Allergy Therapeutics | Update on funding and preliminary results |
07:00 | 17-09-2024 | AGY | Allergy Therapeutics | Progression of patient cohorts in PROTECT Trial |
07:00 | 27-08-2024 | AGY | Allergy Therapeutics | Update on funding |
07:00 | 22-07-2024 | AGY | Allergy Therapeutics | Appointment of Nominated Adviser and Sole Broker |
07:01 | 22-07-2024 | AGY | Allergy Therapeutics | Trading update for the year ended 30 June 2024 |
14:22 | 04-07-2024 | AGY | Allergy Therapeutics | Launch of new Company Long Term Incentive Plan |
07:00 | 27-06-2024 | AGY | Allergy Therapeutics | Appointment of Non-Executive Director |
07:00 | 10-06-2024 | AGY | Allergy Therapeutics | Progression of patient cohorts in PROTECT Trial |
07:00 | 03-06-2024 | AGY | Allergy Therapeutics | Successful meetings with Paul Ehrlich Institut |
07:00 | 07-05-2024 | AGY | Allergy Therapeutics | Further detail from G306 Phase III field trial |
07:00 | 03-04-2024 | AGY | Allergy Therapeutics | Director Resignation |
07:00 | 27-03-2024 | AGY | Allergy Therapeutics | Interim Results for six months ended 31 Dec 2023 |
07:00 | 27-03-2024 | AGY | Allergy Therapeutics | Update on funding |
08:59 | 12-03-2024 | AGY | Allergy Therapeutics | VLP Peanut PROTECT Trial Update |
07:00 | 11-03-2024 | AGY | Allergy Therapeutics | Appointment of Shaun Furlong to Board of Directors |
13:49 | 08-03-2024 | AGY | Allergy Therapeutics | Result of AGM |
07:00 | 14-02-2024 | AGY | Allergy Therapeutics | Half-Year Trading Update 2024 |
15:07 | 09-02-2024 | AGY | Allergy Therapeutics | Notice of 2023 Annual General Meeting |
07:30 | 30-01-2024 | AGY | Allergy Therapeutics | Restoration - Allergy Therapeutics plc |
07:00 | 30-01-2024 | AGY | Allergy Therapeutics | Publication of Annual Report and Accounts 2023 |
12:29 | 04-01-2024 | AGY | Allergy Therapeutics | Total Voting Rights |
07:30 | 02-01-2024 | AGY | Allergy Therapeutics | Suspension - Allergy Therapeutics plc |
12:01 | 27-12-2023 | AGY | Allergy Therapeutics | Amendment to existing Facility Agreement |
12:48 | 15-12-2023 | AGY | Allergy Therapeutics | Annual Report and Accounts Delayed |
16:54 | 13-12-2023 | AGY | Allergy Therapeutics | PDMR dealing and Total Voting Rights |
07:00 | 13-12-2023 | AGY | Allergy Therapeutics | G306 Phase III trial meets key endpoints |
07:00 | 11-12-2023 | AGY | Allergy Therapeutics | Update on funding |
07:00 | 01-12-2023 | AGY | Allergy Therapeutics | Total Voting Rights |
15:03 | 28-11-2023 | AGY | Allergy Therapeutics | Holding(s) in Company |
07:00 | 14-11-2023 | AGY | Allergy Therapeutics | G306 Grass Phase III trial meets primary endpoint |
13:22 | 10-11-2023 | AGY | Allergy Therapeutics | Director/PCA Dealing |
13:11 | 10-11-2023 | AGY | Allergy Therapeutics | Holding(s) in Company |
07:00 | 10-11-2023 | AGY | Allergy Therapeutics | Offer Closure |
10:48 | 09-11-2023 | AGY | Allergy Therapeutics | Exercise of Options and Total Voting Rights |
07:00 | 06-11-2023 | AGY | Allergy Therapeutics | Update on funding |
17:17 | 20-10-2023 | AGY | Allergy Therapeutics | Holding(s) in Company |
07:00 | 19-10-2023 | AGY | Allergy Therapeutics | Posting of Offer Document |
15:03 | 16-10-2023 | AGY | Allergy Therapeutics | Holding(s) in Company |
08:01 | 16-10-2023 | AGY | Allergy Therapeutics | Unconditional Mandatory Cash Offer |
07:00 | 13-10-2023 | AGY | Allergy Therapeutics | Result of Open Offer and Subscription |
12:04 | 27-09-2023 | AGY | Allergy Therapeutics | Publication of Open Offer Circular – Amendment |
07:01 | 27-09-2023 | AGY | Allergy Therapeutics | Publication of Open Offer Circular |
07:00 | 27-09-2023 | AGY | Allergy Therapeutics | Unaudited Preliminary Results 2023 |
07:00 | 26-09-2023 | AGY | Allergy Therapeutics | Phase I VLP Peanut PROTECT trial progress |
07:00 | 22-09-2023 | AGY | Allergy Therapeutics | Satisfaction of FDI clearance conditions |
07:00 | 10-08-2023 | AGY | Allergy Therapeutics | Trading update for the year ended 30 June 2023 |
13:12 | 10-07-2023 | AGY | Allergy Therapeutics | Appointment of Chief Financial Officer |
07:30 | 19-06-2023 | AGY | Allergy Therapeutics | Restoration - Allergy Therapeutics PLC |
07:01 | 19-06-2023 | AGY | Allergy Therapeutics | Interim Results and Lifting Suspension in Trading |
07:00 | 19-06-2023 | AGY | Allergy Therapeutics | Publication of Annual Report and Accounts 2022 |